[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia]
- PMID: 15010998
- DOI: 10.1007/s00292-003-0677-y
[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia]
Abstract
To elucidate the effect of first-line treatment with interferon (IFN), hydroxyurea (HU) and the tyrosine kinase inhibitor imatinib (STI571) on angiogenesis, we studied bone marrow (BM) biopsies in 104 patients with chronic myelogenous leukemia (CML) and 138 patients before and after allogeneic BM transplantation (BMT). After immunostaining (CD34) and morphometric analysis in comparison with a control group, CML specimens showed an increased vascularity and conspicuous morphological abnormalities of microvessels. A close relationship between microvessels and fiber density was detectable in initial biopsies and also in repeatedly performed examinations following therapy. Monotherapy by imatinib and HU generated a significant reduction of microvessels and reticulin fibers in contrast to changes after IFN administration or combination regimens of IFN and HU. A persistence of numerical and structural anomalies of vasculature was observable even several months after BMT. These anomalies shed some light on disturbances of the stroma compartment after myeloablative therapy. The relationship between BM vascularity and fibers is probably dependent on concomitant changes of megakaryopoiesis as the source of various mediators involved in the development of myelofibrosis and neo-angiogenesis acting within a complex functional network.
Similar articles
-
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.Blood. 2004 May 1;103(9):3549-51. doi: 10.1182/blood-2003-08-2734. Epub 2004 Jan 15. Blood. 2004. PMID: 14726401
-
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.Histol Histopathol. 2004 Oct;19(4):1277-88. doi: 10.14670/HH-19.1277. Histol Histopathol. 2004. PMID: 15375771 Review.
-
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.Am J Clin Pathol. 2003 Jun;119(6):833-41. doi: 10.1309/A4RG-P4LF-12GG-H8MW. Am J Clin Pathol. 2003. PMID: 12817431 Clinical Trial.
-
Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.Blood. 2002 Jan 1;99(1):381-3. doi: 10.1182/blood.v99.1.381. Blood. 2002. PMID: 11756197
-
[Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. doi: 10.1254/fpj.122.482. Nihon Yakurigaku Zasshi. 2003. PMID: 14639002 Review. Japanese.
Cited by
-
[Hematological side effects of tyrosine kinase inhibition using imatinib].Pathologe. 2006 Feb;27(1):40-6. doi: 10.1007/s00292-005-0806-x. Pathologe. 2006. PMID: 16421705 German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical